CTLA4 and neoplasm: Table 3 shows the incidence of HPD in patients treated with immunotherapy (PD-1/PD-L1 inhibitors, CTLA-4 inhibitors) in some of the studies which included patients with NSCLC, and some of the studies which included multiple tumor types including NSCLC.